These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24767223)

  • 1. Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients.
    Son BJ; Lee SY; Yoon JS
    Can J Ophthalmol; 2014 Apr; 49(2):167-73. PubMed ID: 24767223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Graves' ophthalmopathy-specific quality of life in Korean patients.
    Choi YJ; Lim HT; Lee SJ; Lee SY; Yoon JS
    Eye (Lond); 2012 Apr; 26(4):544-51. PubMed ID: 22241019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease.
    Fayers T; Dolman PJ
    Br J Ophthalmol; 2011 Dec; 95(12):1670-4. PubMed ID: 21951566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
    Smith TJ; Cockerham K; Barretto N; Hirst A; Oliver L; Enstone A; Brandolini G; Taylor SD; Holt RJ
    Endocr Pract; 2024 May; 30(5):470-475. PubMed ID: 38341128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
    Weng CY; Li ZF; Hu SD; Luo YS; Feng XT; Zhong Q; Zhang Q; Shen J
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):577-583. PubMed ID: 31365979
    [No Abstract]   [Full Text] [Related]  

  • 6. Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease.
    Fayers T; Fayers PM; Dolman PJ
    Orbit; 2016 Dec; 35(6):328-334. PubMed ID: 27599688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
    Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
    Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement Properties of the Persian Translated Version of Graves Orbitopathy Quality of Life Questionnaire: A Validation Study.
    Kashkouli MB; Karimi N; Aghamirsalim M; Abtahi MB; Nojomi M; Shahrad-Bejestani H; Salehi M
    Ophthalmic Epidemiol; 2017 Feb; 24(1):3-10. PubMed ID: 28001456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
    Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
    Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing quality of life in Taiwanese patients with Graves' ophthalmopathy.
    Lin IC; Lee CC; Liao SL
    J Formos Med Assoc; 2015 Nov; 114(11):1047-54. PubMed ID: 24434244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States.
    Smith TJ; Cockerham K; Lelli G; Choudhary C; Taylor S; Barretto N; Enstone A; Oliver L; Lynch J; Holt RJ
    JAMA Ophthalmol; 2023 Feb; 141(2):159-166. PubMed ID: 36580313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.
    Delfino LC; Zunino A; Sapia V; Croome MDCS; Ilera V; Gauna AT
    Arch Endocrinol Metab; 2017; 61(4):374-381. PubMed ID: 28225858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 14. The Psychosocial and Clinical Outcomes of Orbital Decompression Surgery for Thyroid Eye Disease and Predictors of Change in Quality of Life.
    Wickwar S; McBain H; Ezra DG; Hirani SP; Rose GE; Newman SP
    Ophthalmology; 2015 Dec; 122(12):2568-76.e1. PubMed ID: 26421706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective and subjective outcomes of strabismus surgery in Graves' orbitopathy: a prospective multicentre study.
    Jellema HM; Saeed P; Mombaerts I; Dolman PJ; Garrity J; Kazim M; Dhrami-Gavazi E; Lyons C; Nieuwkerk P; Mourits MP
    Acta Ophthalmol; 2017 Jun; 95(4):386-391. PubMed ID: 28133945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States.
    Wang Y; Sharma A; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Massry G; Douglas RS
    Ophthalmol Ther; 2021 Mar; 10(1):75-87. PubMed ID: 33196932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States.
    Wang Y; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Douglas RS
    Endocr Pract; 2022 Sep; 28(9):842-846. PubMed ID: 35714862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in a german graves orbitopathy population.
    Ponto KA; Hommel G; Pitz S; Elflein H; Pfeiffer N; Kahaly GJ
    Am J Ophthalmol; 2011 Sep; 152(3):483-490.e1. PubMed ID: 21676374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vision-related quality of life tends to be more severely impaired in patients with dysthyroid optic neuropathy.
    Du Y; Ye H; Li K; Xiao X; Chen R; He JF; Yang H
    Curr Eye Res; 2014 May; 39(5):532-6. PubMed ID: 24215175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.